Gloucestershire Hospitals NHS Foundation Trust

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Head and neck cancer2 trials
• Macular degeneration2 trials
• Alopecia areata1 trial
• Barrett's oesophagus1 trial
• Diabetic eye disease1 trial
• Gastric and oesophageal cancer1 trial
• Parkinson disease1 trial
• Primary biliary cholangitis1 trial

Phase

• Phase 22 trials
• Phase 31 trial

Status

• Completed5 trials
• Active, not recruiting2 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• University of Exeter3 trials
• Calliditas Therapeutics Suisse SA1 trial
• Frank G. Holz1 trial
• Gloucestershire Hospitals NHS Foundation Trust1 trial
• ONL Therapeutics1 trial
• and 2 more

Running trials

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· ONL Therapeutics· Source

  Contact: Study Coordinator

• Active, not recruiting

  Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

  NCT06531109· Pfizer· Source

• Active, not recruiting

  Development of Novel Clinical Endpoints in Intermediate AMD

  NCT03349801· Frank G. Holz· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration1 recruiting

Closed trials

• Terminated

  DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (In Vivo Phase)

  NCT05010369· University of Exeter· Source

• Completed

  Applied Conversion Equation for Optical Coherence Tomography

  NCT07816627· Gloucestershire Hospitals NHS Foundation Trust· Source

• Completed

  Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy

  NCT03468634· University of Exeter· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (Ex Vivo Phase)

  NCT04162431· University of Exeter· Source

• Completed

  CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

  NCT04226248· Phase 3· University of Bristol· Source